目的 初步探讨先天性心脏病患儿血清Apelin 水平与肺动脉压的关系.方法 手术治疗的先心病患儿126 例,检测患儿术前及术后第7 天的血清Apelin 水平.建立体外循环前检测并计算肺动脉收缩压/体循环收缩压(Pp/Ps)的比值,依据Pp/Ps 分组:无肺动脉高组压(PAH)组、轻度PAH 组、中度PAH 组和重度PAH 组;术后第7 天超声心动图估测肺动脉平均压(PAMP).结果 无PAH,以及轻、中、重度PAH 各组术前及术后的血清Apelin 水平依次降低,差异有统计学意义(P<0.05);术后第7 天各组血清Apelin 水平较术前均升高,差异有统计学意义(P<0.05).术前及术后第7 天的血清Apelin 水平与肺动脉压均呈负相关(r=-0.51,-0.54,P<0.05).结论 先心病患儿并发肺动脉高压及其发展与血清Apelin 水平降低有关系,血清Apelin 对诊断先心病患儿是否并发肺动脉高压及其程度的意义值得深入研究.
Abstract
Objective To preliminarily investigate the relationship between serum apelin level and pulmonary artery pressure in children with congenital heart disease. Methods One hundred and twenty-six children with congenital heart disease undergoing surgical treatment were enrolled as subjects. The serum level of apelin was determined before surgery and at 7 days after surgery. The ratio of pulmonary artery systolic pressure to aortic systolic pressure (Pp/Ps) was calculated before extracorporeal circulation. According to the Pp/Ps value, patients were classified into non-pulmonary arterial hypertension (PAH) group, mild PAH group, moderate PAH group, and severe PAH group. Pulmonary artery mean pressure was estimated by echocardiography at 7 days after surgery. Results The non-PAH group had the highest serum level of apelin before and after surgery, followed by the mild PAH group, moderate PAH group, and severe PAH group (P<0.05). All groups had significantly increased serum levels of apelin at 7 days after surgery (P<0.05). The serum level of apelin was negatively correlated with pulmonary artery pressure before surgery (r=-0.51, P<0.05) and at 7 days after surgery (r=-0.54, P<0.05). Conclusions The decrease in serum apelin level is associated with the development of pulmonary hypertension in children with congenital heart disease. The significance of serum apelin in predicting the development and degree of pulmonary hypertension in children with congenital heart disease deserves further studies.
关键词
先天性心脏病 /
肺动脉高压 /
Apelin /
儿童
Key words
Congenital heart disease /
Pulmonary hypertension /
Apelin /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 刘瀚旻. 先天性心血管畸形的肺血管重构: 一个历久弥新的话题[J]. 中国当代儿科杂志, 2013, 15(10): 805-809.
[2] Tabib A, Khorgami MR, Meraji M, et al. Accuracy of Dopplerderived indices in predicting pulmonary vascular resistance in children with pulmonary hypertension secondary to congenital heart disease with left-to-right shunting[J]. Pediatr Cardiol, 2014, 35(3): 521-529.
[3] 王晋旺, 李波, 张振忠, 等. 米力农对先天性心脏病肺动脉高压患者术前血流动力学的效应[J]. 中国药物与临床, 2012, 12(1): 113-115.
[4] Myers PO, Tissot C, Beghetti M. Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease[J]. Circ J, 2013, 78(1): 4-11.
[5] 朱晨曦, 杨京华, 王增智. 等. 贝前列素钠与西地那非治疗肺动脉高压的疗效及安全性研究[J]. 临床心血管病杂志, 2015, 31(6): 639-644.
[6] Betkier-Lipińska K, Ryczek R, Kwasiborski P, et al. Pulmonary arterial hypertension: modern diagnostics and therapy--Part 1[J]. Pol Merkur Lekarski, 2013, 34(204): 355-359.
[7] Farkas L, Gauldie J, Voelkel N F, et al. Pulmonary hypertension and idiopathic pulmonary fibrosis, a tale of angiogenesis, apoptosis, and growth factors[J]. Am J Respir Cell Mol Biol, 2011, 45(1): 1-15.
[8] Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society[J]. Circulation, 2015, 132(21): 2037-2099.
[9] Lau EM, Manes A, Celermajer DS, et al. Early detection of pulmonary vascular disease in pulmonary Arterial hypertension: time to move forward[J]. Eur Heart J, 2011, 32(20): 2489-2498.
[10] Bossone E, Ferrara F, Grünig E. Echocardiography in pulmonary hypertension[J]. Curr Opin Cardiol, 2015, 30(6): 574-586.
[11] Dai HL, Guo Y, Guang XF, et al. The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease[J]. Cardiology, 2013, 124(4): 208-212.
[12] Giannakoulas G, Mouratoglou SA, Gatzoulis MA, et al. Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. a systematic review. Int J Cardiol, 2014, 174(3): 618-623.
[13] Schuuring MJ, van Riel AC, Vis JC, et al. New predictors of mortality in adults with congenital heart disease and pulmonary hypertension: Midterm outcome of a prospective study.Int J Cardiol, 2015, 181C(2014): 270-276.
[14] Bertrand C, Valet P, Castan-Laurell I. Apelin and energy metabolism[J]. Front Physiol, 2015, 6(115): 1-5.
[15] Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system[J]. Trends Pharmacol Sci, 2015, 36(9): 560-567.
[16] 张爱元, 季祥武, 李丽英, 等. 心力衰竭患者心功能与血浆 Apelin 水平的关系[J]. 中国心血管病研究, 2010, 8(2): 112-114.
[17] Zhang J, Liu Q, Hu X, et al. Apelin/APJ signaling promotes hypoxia-induced proliferation of endothelial progenitor cells via phosphoinositide-3 kinase/Akt signaling[J]. Mol Med Rep, 2015, 12(3): 3829-3834.
[18] Fan XF, Xue F, Zhang YQ, et al. The Apelin-APJ axis is an endogenous counterinjury mechanism in experimental acute lung injury[J]. Chest, 2015, 147(4): 969-978.
[19] Cao J, Li H, Chen L.Targeting drugs to APJ receptor: the prospect of treatment of hypertension and other cardiovascular diseases[J]. Curr Drug Targets, 2015, 16(2): 148-155.
[20] 梁园园, 叶建荣, 马海平, 等. 先天性心脏病伴肺动脉高压患儿围术期中性粒细胞明胶酶相关脂质运载蛋白水平的变化[J]. 中国当代儿科杂志, 2013, 15(10): 827-830.
[21] 卢荔红, 关瑞锦, 吴志勇, 等. 先天性心脏病并发重度肺动脉高压介入封堵联合伐地那非的应用研究[J]. 临床心血管病杂志, 2012, 28(7): 514-517.
[22] Blok IM, van Riel AC, Mulder BJ, et al. Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions[J]. Expert Rev Cardiovasc Ther, 2015, 13(12): 1377-1392.
[23] 徐小红, 朱智明. Apelin 与肺动脉高压[J]. 医学综述, 2014, 20(1): 1-3.
[24] 毛孙忠, 洪林, 胡良冈, 等. Apelin 对大鼠低氧性肺动脉高压的作用及与NO 途径的关系[J]. 生理学报, 2009, 61(5): 480-484.
[25] Chandra SM, Razavi H, Kim J, et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol, 2011, 31(4): 814-820.
[26] Alastalo TP, Li M, Perez JP, et al. Disruption of PPARγ/β-cateninmediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival[J]. J Clin Invest, 2011, 121(9): 3735-3746.
[27] Zeng X, Yu SP, Taylor T, et al. Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis[J]. Stem Cell Res, 2012, 8(3): 357-367.
[28] 黄维佳. 5-HTT 与肺动脉平滑肌细胞凋亡在左向右分流肺动脉高压大鼠中关系的研究[D]. 南宁: 广西医科大学, 2011.
[29] Folino A, Montarolo PG, Samaja M, et al. Effects of apelin on the cardiovascular system[J]. Heart Fail Rev, 2015, 20(4): 505-518.
PDF(1326 KB)
